Jonathan Van-Tam on COVID’s Next Phase - Summary - MDSpire
Commentary & Perspectives

Jonathan Van-Tam on COVID’s Next Phase

Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19

Share

Professor Sir Jonathan Van-Tam, former Deputy Chief Medical Officer for England, discusses the evolving landscape of COVID-19 vaccination, specifically the introduction of Sanofi's Nuvaxovid vaccine in the UK’s Spring 2026 program. He highlights that while COVID-19 remains a public health concern akin to seasonal flu, the introduction of diverse vaccine technologies—including protein-based options like Nuvaxovid—could address vaccine hesitancy. He emphasizes lessons learned from the pandemic about the importance of having multiple vaccine platforms and the growing need for adult immunization.

Original Source(s)

Jonathan Van-Tam on COVID’s Next Phase

  • by James Strachan, Julian Upton

  • April 14, 2026

Related Content

Expanding Access to TB Testing

WHO recommends near point-of-care tests, tongue swabs, and pooling strategies

  • April 14, 2026

  • 2 min
Antivirals Linked to Lower Hospitalization in Influenza

Matched cohort study in nonhospitalized patients

Raman Spectroscopy Moves to the Front Line of Pandemic Preparedness

Comprehensive review highlights label-free viral detection – and the hurdles to real-world deployment

  • April 13, 2026

  • 2 min